The RNA Transcript, March 28, 2022 |
|
Five U-M junior and early career scientists presented their research in data blitzes: Chase Weidmann, Assistant Professor, Biological Chemistry; Rene Tan, Graduate Student, Biological Chemistry, Sethu Pitchiaya, Assistant Professor, Urology and Pathology; Nico Gomez, Graduate Student, Neurology; and Stephanie Moon, Assistant Professor, Human Genetics.
The panel discussion Future of RNA Therapeutics was moderated by John Androsavich, Pfizer Global Lead, RNA Medicine.
The MiSciWriters, a student organization dedicated to improving public understanding of science, blogged the keynote presentations:
|
|
TODAY! U-M RNA Innovation Seminar Series
|
|
|
|
Marvelous U: Canonical and non-canonical functions of uridine modifying enzymes in health and disease
TODAY Monday, March 28, 2022
4:00 pm - 5:00 pm
BSRB, ABC Seminar rooms (hybrid)
|
|
Harvard Initiative for RNA Medicine |
|
|
|
microManaging cell differentiation
Tuesday, March 29, 2022
3:00 pm - 4:00 pm
|
|
|
|
Cryo-EM Structural Analysis of Neuronal and Inducible Nitric Oxide Synthase Complexes
Wednesday, March 30, 2022
2:00 pm - 3:00 pm
|
|
|
|
How direct small molecule binding to mRNAs direct expression
Friday, April 1, 2022
12:00 pm - 1:00 pm
1640 Chemistry Dow Lab
|
|
U-M Biological Chemistry Seminar |
|
|
|
Tuesday, April 5, 2022
12:00 pm - 1:00 pm
5330 MS I
|
|
|
|
Genetic mechanisms of pediatric renovascular hypertension
Tuesday, April 5, 2022
4:00 pm - 5:00 pm
BSRB, ABC Seminar rooms ( hybrid) |
|
----Wednesday, April 6, 2022
----4:00 pm - 5:00 pm
|
|
“NERD-seq: A novel approach of Nanopore direct RNA sequencing that expands representation of non-coding RNAs”
"Dissecting the role of SINE non-coding RNAs in brain health and disease"
|
|
|
|
|
Chaperoning Protein Folding with RNA, and Fun with Foldit
Friday, April 8, 2022
12:00 pm - 1:00 pm
1640 Chemistry Dow Lab
|
|
Pfizer is seeking proposals for the advancement of RNA therapeutics and the development of the next generation of RNA medicines |
|
Submissions invited for novel target concepts and therapeutic strategies amenable to RNA based approaches (mRNA, circular RNA, gene editing), in the following areas of interest:
- Cellular reprogramming:
- Cancer vaccines
- Infectious Disease Vaccines
- Chronic or Rare Kidney Disease (Focal Segmental Glomerulosclerosis, IgA Nephropathy, Alport Syndrome, or Autosomal Dominant Polycystic Kidney Disease)
- Rare Liver Diseases and Rare Neuromuscular Diseases
- Repeat Expansion Diseases (e.g. Huntington’s disease, Friedreich’s ataxia, ALS, myotonic dystrophy)
- Preference given to targets not amenable to small or large molecule intervention
|
|
|
|
Our members' publications are available through Altmetrics. Queries are currently available: CRISPR, microRNA, molecule, RNA, RNA therapeutics, transcriptome, and translation. Below are recent highlights.
|
|
Immediate postdoc opening to incubate a CRISPR-based nucleic acid detection technology in Dr. Ailong Ke's laboratory at Cornell University |
|
There is a postdoctoral opening in Dr. Ailong Ke's laboratory at Cornell University to commercialize a CRISPR-based nucleic acid detection technology. The qualified candidate will work with Dr. Ke to secure funding through the Cornell Ignite Postdoc for Ventures program. This newly established program provides two-years of salary, research, and mentorship support to train postdocs with entrepreneurial outlooks to start technology ventures. The successful candidate will report to Dr. Ke during the first year to identify the market needs and to generate the necessary data to support product development. The candidate will then report to the director of the McGovern Incubator to bring the product to the market.
The candidate is expected to have a strong research record, strong communication skills, and a strong interest in a career path in biotech industry. The candidate is expected to pick up business, market analysis, and marketing skills in fast pace. Strong background in biochemistry, bioinformatics, microbiology, or microfluidics is considered a plus. To qualify for the Ignite program, the candidate should be expecting a Ph.D. degree within six months of the application, or a current postdoctoral fellow. The interested candidates should send your CV and names of three referees through email to me ( ak425@cornell.edu) for further consideration. Application deadline is March 30th, 2022.
|
|
Multiple new postdoctoral positions in Dr. Rebecca Schulman's group at Johns Hopkins University |
|
The Schulman group at Johns Hopkins University is looking for multiple postdoctoral scholars to create new adaptive and dynamic materials and self-assembled machines by combining programmable, dynamic DNA assembly and disassembly and dynamic DNA circuits. The projects are open-ended. Work in the lab is likely to span design, quantitative modeling, and experimental characterization and analysis. Experimental techniques could include time-lapse fluorescence microscopy, TEM, and fluorescence spectroscopy. Interest in developing and making use of experimental automation for high-throughput characterization is a plus. Interested candidates can email rschulm3@jhu.edu to discuss the projects, the research group or to submit an application (please include a cover letter and CV). |
|
RiPCA: An Assay for the Detection of RNA-Protein Interactions in Live Cells, Rosenblum, S. L., & Garner, A. L. (2022) Current Protocols, e358 (2). DOI: 10.1002/cpz1.358
Increasing interest in studying and modulating the interactions between RNAs and their RNA-binding proteins has indicated the need for enabling technologies. Existing means of detecting RNA-protein interactions (RPIs) are often limited to biochemical or post-lysis methods or cell-based methods that require the addition of an RNA-based affinity tag, such as the MS2 hairpin, precluding them from use in detecting small or highly processed RNAs. Taking advantage of bioorthogonal chemistry- and split-luciferase-based technologies, we developed an assay for the detection of RPIs in live cells. This article details the protocol and design considerations for RiPCA, or RNA interaction with Protein-mediated Complementation Assay.
|
|
|
|
|
|
|
